NewAmsterdam Pharma  N.V. logo

NewAmsterdam Pharma N.V.

NAMS | NASDAQ
Chart Builder DCF Calculator
$20.32
+$0.26 (+1.30%)
Nov 2, 2026, 10:35 AM ET · Market open
Fiscal Year
Period Ending
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
Cash & Equivalents
490M 771.74M 340.45M 467.73M 60.38M 1.37M
Short-Term Investments
146.24M 62.45M n/a n/a n/a n/a
Long-Term Investments
n/a n/a n/a n/a 138.02M 138M
Other Long-Term Assets
92.61M n/a 35K 156K -137.2M n/a
Receivables
23.15M 21.31M 1.88M n/a 5.51M n/a
Inventory
n/a n/a n/a n/a n/a n/a
Other Current Assets
1.32M n/a n/a 2.07M -627.81K n/a
Total Current Assets
675.7M 863.41M 346.79M 477.98M 66.96M 1.87M
Property-Plant & Equipment
568K 673K 101K 154K 216.08K n/a
Goodwill & Intangibles
407K 534K 170K 208K n/a n/a
Total Long-Term Assets
93.58M 1.21M 306K 518K 1.03M 138M
Total Assets
769.28M 864.62M 347.1M 478.5M 67.99M 139.87M
Account Payables
8.97M 4.74M 16.92M 11.85M 7.07M 162.48K
Deferred Revenue
3.99M 6.01M 8.94M n/a n/a n/a
Short-Term Debt
136K n/a n/a n/a n/a n/a
Other Current Liabilities
72.69M 91.03M 15.96M 18.02M n/a 74.04K
Total Current Liabilities
85.79M 106.92M 49.9M 36.06M 11.24M 236.52K
Long-Term Debt
66K n/a n/a n/a n/a n/a
Other Long-Term Liabilities
n/a n/a 7.79M 12.31M n/a 12.17M
Total Long-Term Liabilities
66K 202K 8.81M 12.37M 126.24K 12.17M
Total Liabilities
85.85M 107.12M 58.7M 48.43M 11.36M 12.41M
Total Debt
202K 448K 60K 126K 186.51K n/a
Book Value
683.43M 757.5M 288.39M 430.07M 56.63M 127.46M
Book Value Per Share
5.97 8.03 3.51 22.68 3.19 7.18
Common Stock
14.28M 13.44M 10.17M 10.06M 128.51K 122.46M
Retained Earnings
-762.39M -558.57M -316.97M -140.04M -39.44M 41.45K
Comprehensive Income
4.79M 4.47M 4.42M 4.42M 672.13K n/a
Shareholders Equity
683.43M 757.5M 288.39M 430.07M 56.63M 127.46M
Total Investments
146.24M 62.45M n/a n/a 138.02M 138M

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.